TAVALISSE® (fostamatinib disodium hexahydrate) tablets

TAVALISSE® (fostamatinib disodium hexahydrate) is the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Click for information on TAVALISSE
Click for Full Prescribing Information

REZLIDHIA® (olutasidenib) capsules

REZLIDHIA (olutasidenib) capsules are indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test.

Click for information on REZLIDHIA
Click for Full Prescribing Information*

*Including Boxed WARNING for differentiation syndrome